CANN vs PETS
Trees Corp. (Colorado) and Petmed Express Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CANN | PETS |
|---|---|---|
| Revenue | $18.1M | $179.0M |
| Net income | $-7.1M | $-57.3M |
| Gross margin | 36.2% | 28.1% |
| Net margin | −39.0% | −32.0% |
| Return on equity | −216.1% | −100.4% |
| Diluted EPS | −$0.06 | −$2.74 |
| Dividend / share | · | $0.00 |
| Payout ratio | · | −0.0% |
| Free cash flow | · | $-33.0M |
| Equity | $148,159 | $28.9M |
| Net debt / equity | 95.41× | · |
| Current ratio | 0.32× | 0.84× |
| Revenue CAGR 5y | 59.9% | −10.0% |
| Profit CAGR 5y | · | · |
PETS bills 9.9× the revenue of CANN, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | CANN | PETS |
|---|---|---|
| FY2023 | $18.1M | $274.1M |
| FY2022 | $13.4M | $247.6M |
| FY2021 | $5.9M | $272.3M |
| FY2020 | $2.4M | $303.6M |
| FY2019 | $3.7M | $284.1M |
| FY2018 | $1.7M | $283.4M |
| FY2017 | $3.5M | $273.8M |
| FY2016 | $3.0M | $249.2M |
| FY2015 | $1.8M | $234.7M |
| FY2014 | $240,206 | $229.4M |
Bottom line
| Fiscal year | CANN | PETS |
|---|---|---|
| FY2023 | $-7.1M | $-7.5M |
| FY2022 | $-9.5M | $5.1M |
| FY2021 | $-8.9M | $18.7M |
| FY2020 | $-7.7M | $23.9M |
| FY2019 | $-15.5M | $25.9M |
| FY2018 | $-17.0M | $37.7M |
| FY2017 | $-8.2M | $37.3M |
| FY2016 | $-10.2M | $23.8M |
| FY2015 | $-8.8M | $20.6M |
| FY2014 | $-6.9M | $17.5M |
12 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2023 | −$255,958,120 | PETS |
| FY2022 | −$234,124,458 | PETS |
| FY2021 | −$266,354,801 | PETS |
| FY2020 | −$301,199,296 | PETS |
| FY2019 | −$280,458,654 | PETS |
| FY2018 | −$281,681,744 | PETS |
| FY2017 | −$270,277,925 | PETS |
| FY2016 | −$246,194,018 | PETS |
| FY2015 | −$232,921,022 | PETS |
| FY2014 | −$229,154,794 | PETS |
| FY2012 | −$227,824,860 | PETS |
| FY2011 | −$238,247,195 | PETS |
PETS has reported the higher revenue in every one of these 12 fiscal years. The gap has widened since the earliest year compared.
12 of 17 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2023 | −36.3 pp | PETS |
| FY2022 | −72.6 pp | PETS |
| FY2021 | −156.5 pp | PETS |
| FY2020 | −330.1 pp | PETS |
| FY2019 | −431.4 pp | PETS |
| FY2018 | −990.4 pp | PETS |
| FY2017 | −247.0 pp | PETS |
| FY2016 | −350.5 pp | PETS |
| FY2015 | −507.1 pp | PETS |
| FY2012 | −498.4 pp | PETS |
PETS has kept the higher net margin in every one of these 10 fiscal years.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
CANN's net margin has been more volatile than PETS's over the 10 comparable fiscal years — 258.7 percentage points of standard deviation against 4.6.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
PETS led in net margin in every one of the 10 comparable fiscal years — a structural lead, not a recent swing.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
CANN's return on equity has been more volatile than PETS's over the 7 comparable fiscal years — 121.8 percentage points of standard deviation against 11.7.
7 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
PETS led in return on equity in every one of the 7 comparable fiscal years — a structural lead, not a recent swing.
7 of 17 comparable fiscal years — a year missing data on either side is not counted.